on Pentixapharm Holding AG (isin : DE000A40AEG0)
Nuclear Medicine Expert Ken Herrmann Joins Pentixapharm's Board
Prof. Dr. Ken Herrmann has officially joined the Supervisory Board of Pentixapharm Holding AG, as announced on October 28, 2024. Herrmann, renowned in the field of nuclear medicine, is also the Head of the Department of Nuclear Medicine at Universitätsklinikum Essen in Germany. His appointment was agreed upon at a shareholder meeting in June 2024, but administrative delays postponed his involvement.
Dr. Andreas Eckert, Executive Chairman of Pentixapharm, expressed enthusiasm for Herrmann's addition. Herrmann's expertise in radiopharmaceuticals is expected to bolster the company's oncology pipeline, which focuses on non-Hodgkin lymphomas treatment and diagnostics through Y90-PentixaTher and Ga68-PentixaFor.
Herrmann brings considerable expertise, having served previously as the Chair of the European Association of Nuclear Medicine's Oncology & Theranostics Committee. He is also a prolific researcher and an established academic presence, further complementing his new role at Pentixapharm.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news